BREVICON 28-DAY
LOE ApproachingNDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 28-DAY is an oral contraceptive tablet approved in 1976 containing norethindrone and ethinyl estradiol. It prevents ovulation through hormonal suppression and is used for pregnancy prevention in women of reproductive age. This is a legacy oral contraceptive product in a mature, highly competitive market.
LOE Approaching
Product is approaching loss of exclusivity with high generic competition (30 competitive pressure score), indicating downsizing of brand support and reduced team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BREVICON offers limited career growth due to LOE approaching and zero linked job openings, suggesting the brand team is stable or contracting. This is a maintenance assignment ideal for cost management and defensive commercial strategy rather than launching or scaling a product.
Brand ManagerProduct Manager
Worked on BREVICON 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.